Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07823127
PHASE2

MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP)

Sponsor: Mirum Pharmaceuticals, Inc.

View on ClinicalTrials.gov

Summary

This study is designed to assess whether the investigational drug maralixibat, is safe and well tolerated in pregnant women with intrahepatic cholestasis of pregnancy (ICP). This is an open-label study where all participants will receive maralixibat.

Official title: MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP) (OASIS)

Key Details

Gender

FEMALE

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2027-01-15

Completion Date

2029-01-12

Last Updated

2026-09-16

Healthy Volunteers

No

Interventions

DRUG

Maralixibat

Maralixibat tablets: 10 mg and 15 mg. Maralixibat oral solution 20 mg/mL. Maralixibat administered orally once or twice daily, with dose adjustments based on response and tolerability, from enrollment until delivery.